Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Clinical evidence

MG-001 phase 2b

81 evidence topics · 11 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using MGC response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline demographics and disease characteristics, mITT population
CharacteristicDescartes-08 (n = 15)Placebo (n = 11)Total (n = 26)
Mean age, years (s.d.)“56.7 (16.39)”View highlighted excerpt for this quote“59.0 (13.96)”View highlighted excerpt for this quote“57.7 (15.16)”View highlighted excerpt for this quote
Female, n (%)“10 (66.7)”View highlighted excerpt for this quote“6 (54.5)”View highlighted excerpt for this quote“16 (61.5)”View highlighted excerpt for this quote
Mean weight, kg (s.d.)“93.83 (20.001)”View highlighted excerpt for this quote“105.37 (27.496)”View highlighted excerpt for this quote“98.71 (23.669)”View highlighted excerpt for this quote
White, non-Hispanic, n (%)“13 (86.7)”View highlighted excerpt for this quote“11 (100.0)”View highlighted excerpt for this quote“24 (92.3)”View highlighted excerpt for this quote
MGFA class IIa at screening, n (%)“0”View highlighted excerpt for this quote“2 (18.2)”View highlighted excerpt for this quote“2 (7.7)”View highlighted excerpt for this quote
MGFA class IIb at screening, n (%)“4 (26.7)”View highlighted excerpt for this quote“1 (9.1)”View highlighted excerpt for this quote“5 (19.2)”View highlighted excerpt for this quote
MGFA class IIIa at screening, n (%)“2 (13.3)”View highlighted excerpt for this quote“5 (45.5)”View highlighted excerpt for this quote“7 (26.9)”View highlighted excerpt for this quote
MGFA class IIIb at screening, n (%)“8 (53.3)”View highlighted excerpt for this quote“3 (27.3)”View highlighted excerpt for this quote“11 (42.3)”View highlighted excerpt for this quote
MGFA class IVa at screening, n (%)“1 (6.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.8)”View highlighted excerpt for this quote
Median age at disease onset, years (range)“55 (16–76)”View highlighted excerpt for this quote“51 (25–71)”View highlighted excerpt for this quote“53 (16–76)”View highlighted excerpt for this quote
Median duration of disease, years (range)“5.5 (2–23)”View highlighted excerpt for this quote“10 (4–26)”View highlighted excerpt for this quote“6 (2–26)”View highlighted excerpt for this quote
Anti-AChR antibody, n (%)“11 (73.3)”View highlighted excerpt for this quote“8 (72.7)”View highlighted excerpt for this quote“19 (73.1)”View highlighted excerpt for this quote
Anti-LRP4 antibody, n (%)“1 (6.7)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“1 (3.8)”View highlighted excerpt for this quote
Triple seronegative, n (%)“3 (20.0)”View highlighted excerpt for this quote“3 (27.3)”View highlighted excerpt for this quote“6 (23.1)”View highlighted excerpt for this quote
Mean QMG score (s.d.)“17.3 (7.31)”View highlighted excerpt for this quote“14.7 (4.03)”View highlighted excerpt for this quote“16.2 (6.17)”View highlighted excerpt for this quote
Mean MG-ADL score (s.d.)“10.5 (3.20)”View highlighted excerpt for this quote“9.8 (2.79)”View highlighted excerpt for this quote“10.2 (3.00)”View highlighted excerpt for this quote
Mean MGC score (s.d.)“16.4 (6.39)”View highlighted excerpt for this quote“15.7 (3.95)”View highlighted excerpt for this quote“16.1 (5.41)”View highlighted excerpt for this quote
Mean MG-QoL-15r score (s.d.)“19.1 (7.62)”View highlighted excerpt for this quote“17.7 (4.73)”View highlighted excerpt for this quote“18.5 (6.48)”View highlighted excerpt for this quote
Diagnosis of thymoma, n (%)“1 (6.7)”View highlighted excerpt for this quote“4 (36.4)”View highlighted excerpt for this quote“5 (19.2)”View highlighted excerpt for this quote
Previous thymectomy, n (%)“4 (26.7)”View highlighted excerpt for this quote“6 (54.5)”View highlighted excerpt for this quote“10 (38.5)”View highlighted excerpt for this quote
Previous MG crisis requiring intubation, n (%)“2 (13.3)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote“2 (7.7)”View highlighted excerpt for this quote
Previous and ongoing MG therapies, mITT population
TherapyDescartes-08 (n = 15)Placebo (n = 11)Total (n = 26)
Previous pyridostigmine, n (%)“9 (60.0)”View highlighted excerpt for this quote“9 (81.8)”View highlighted excerpt for this quote“18 (69.2)”View highlighted excerpt for this quote
Previous prednisone, n (%)“7 (46.7)”View highlighted excerpt for this quote“5 (45.5)”View highlighted excerpt for this quote“12 (46.2)”View highlighted excerpt for this quote
Previous other immunosuppressants, n (%)“7 (46.7)”View highlighted excerpt for this quote“9 (81.8)”View highlighted excerpt for this quote“16 (61.5)”View highlighted excerpt for this quote
Previous complement inhibitor, n (%)“3 (20.0)”View highlighted excerpt for this quote“5 (45.5)”View highlighted excerpt for this quote“8 (30.8)”View highlighted excerpt for this quote
Previous FcRn inhibitor, n (%)“5 (33.3)”View highlighted excerpt for this quote“4 (36.4)”View highlighted excerpt for this quote“9 (34.6)”View highlighted excerpt for this quote
Previous intravenous immunoglobulin, n (%)“11 (73.3)”View highlighted excerpt for this quote“9 (81.8)”View highlighted excerpt for this quote“20 (76.9)”View highlighted excerpt for this quote
Previous plasma exchange, n (%)“3 (20.0)”View highlighted excerpt for this quote“6 (54.5)”View highlighted excerpt for this quote“9 (34.6)”View highlighted excerpt for this quote
Ongoing pyridostigmine, n (%)“11 (73.3)”View highlighted excerpt for this quote“7 (63.6)”View highlighted excerpt for this quote“18 (69.2)”View highlighted excerpt for this quote
Ongoing prednisone, n (%)“9 (60.0)”View highlighted excerpt for this quote“4 (36.4)”View highlighted excerpt for this quote“13 (50.0)”View highlighted excerpt for this quote
Ongoing azathioprine, n (%)“3 (20.0)”View highlighted excerpt for this quote“2 (18.2)”View highlighted excerpt for this quote“5 (19.2)”View highlighted excerpt for this quote
Ongoing mycophenolate mofetil, n (%)“3 (20.0)”View highlighted excerpt for this quote“6 (54.5)”View highlighted excerpt for this quote“9 (34.6)”View highlighted excerpt for this quote
Ongoing complement inhibitor, n (%)“4 (26.7)”View highlighted excerpt for this quote“1 (9.1)”View highlighted excerpt for this quote“5 (19.2)”View highlighted excerpt for this quote
Number of concomitant MG therapies, median (range)“2 (1–4)”View highlighted excerpt for this quote“2 (1–5)”View highlighted excerpt for this quote“2 (1–5)”View highlighted excerpt for this quote
Baseline characteristics of all randomized participants (safety population)
CharacteristicPlacebo (n=16)Descartes-08 (n=20)
Female, % (n)“62.5 (10)”“55.0 (11)”
Age, years, mean (SD)“57.8 (14.4)”“59.4 (14.7)”
Median duration of disease, years (range)“5 (1–23)”“6 (0–26)”
MGFA class III at screening, % (n)“68.8 (11)”“70.0 (14)”
AChR+, % (n)“75.0 (12)”“80.0 (16)”
Sero-negative, % (n)“25.0 (4)”“15.0 (3)”
Diagnosis of thymoma, % (n)“31.3 (5)”“10.0 (2)”
Previous thymectomy, % (n)“50.0 (8)”“30.0 (6)”
Previous FcRn antagonist, % (n)“37.5 (6)”“30.0 (6)”
Previous complement inhibitor, % (n)“37.5 (6)”“15.0 (3)”
Efficacy results
Primary endpoint and month 3 score changes, mITT population (Descartes-08 n = 15; placebo n = 11)
Outcome at month 3Descartes-08 (n = 15)Placebo (n = 11)
MGC score, baseline, mean (s.d.)“16.4 (6.39)”View highlighted excerpt for this quote“15.7 (3.95)”View highlighted excerpt for this quote
MGC score, month 3, mean (s.d.)“11.4 (8.57)”View highlighted excerpt for this quote“13.5 (8.48)”View highlighted excerpt for this quote
MGC change from baseline at month 3, mean (s.d.)“−5.0 (6.67)”View highlighted excerpt for this quote“−2.3 (7.73)”View highlighted excerpt for this quote
MGC responder (≥5-point reduction), n (%)“10 (66.7)”View highlighted excerpt for this quote“3 (27.3)”View highlighted excerpt for this quote
MG-ADL score, baseline, mean (s.d.)“10.5 (3.20)”View highlighted excerpt for this quote“9.8 (2.79)”View highlighted excerpt for this quote
MG-ADL score, month 3, mean (s.d.)“6.4 (4.31)”View highlighted excerpt for this quote“8.2 (3.82)”View highlighted excerpt for this quote
MG-ADL change from baseline at month 3, mean (s.d.)“−4.1 (3.38)”View highlighted excerpt for this quote“−1.6 (4.06)”View highlighted excerpt for this quote
QMG score, baseline, mean (s.d.)“17.3 (7.3)”View highlighted excerpt for this quote“14.7 (4.03)”View highlighted excerpt for this quote
QMG score, month 3, mean (s.d.)“13.4 (7.53)”View highlighted excerpt for this quote“13.2 (5.12)”View highlighted excerpt for this quote
QMG change from baseline at month 3, mean (s.d.)“−3.9 (4.37)”View highlighted excerpt for this quote“−1.5 (4.27)”View highlighted excerpt for this quote
MG-ADL and QMG changes through month 12, Descartes-08 group, mITT population (open-label follow-up)
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events, day 1 to month 3, safety population
Event, n (%)Descartes-08 (n = 20)Placebo (n = 16)
Any AE“17 (85.0)”View highlighted excerpt for this quote“13 (81.3)”View highlighted excerpt for this quote
SAE“5 (25.0)”View highlighted excerpt for this quote“3 (18.8)”View highlighted excerpt for this quote
Any AE leading to discontinuation of study drug“1 (5.0)”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Any infection“8 (40.0)”View highlighted excerpt for this quote“6 (37.5)”View highlighted excerpt for this quote
Upper respiratory infection“3 (15.0)”View highlighted excerpt for this quote“4 (25.0)”View highlighted excerpt for this quote
HSV reactivation“3 (15.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
COVID-19 infection“1 (5.0)”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Catheter-related infection“1 (5.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Urinary tract infection“0”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Any IRR“16 (80.0)”View highlighted excerpt for this quote“9 (56.3)”View highlighted excerpt for this quote
Headache“10 (50.0)”View highlighted excerpt for this quote“7 (43.8)”View highlighted excerpt for this quote
Nausea“9 (45.0)”View highlighted excerpt for this quote“4 (25.0)”View highlighted excerpt for this quote
Fever“11 (55.0)”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Chills“12 (60.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Myalgia“7 (35.0)”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Fatigue“7 (35.0)”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Limb swelling“2 (10.0)”View highlighted excerpt for this quote“2 (12.5)”View highlighted excerpt for this quote
Diarrhea“3 (15.0)”View highlighted excerpt for this quote“1 (6.3)”View highlighted excerpt for this quote
Overall adverse events and grade 3 events, safety population

“Adverse event (AE) rates were similar between groups, with 17 of 20 (85.0%) participants in the Descartes-08 group and 13 of 16 (81.3%) participants in the placebo group reporting at least one AE during the study (Table 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Most AEs were mild or moderate (Common Terminology Criteria for AEs (CTCAE) grades 1–2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among 20 participants in the safety population randomized to Descartes-08 and 16 participants randomized to placebo, 5 (25.0%) and 2 (12.5%), respectively, experienced a grade 3 AE.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the Descartes-08 group, grade 3 AEs included a vasovagal reaction, a bacterial infection, fever, a herpes simplex virus (HSV) reactivation and a thromboembolic event (thrombosis of a central venous port placed several years before enrollment).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Meanwhile, grade 3 AEs reported in the placebo group included disease exacerbation and urinary tract infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of these, only the case of fever was deemed possibly treatment-related.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Serious adverse events and absence of grade 4 or 5 events, safety population
Treatment-emergent adverse events, AChR antibody-positive participants
Event, n (%)Descartes-08 (n=16)Placebo (n=12)
Any AE“16 (100)”“12 (100)”
Serious AE“4 (25.0)”“2 (16.7)”
Any AE leading to discontinuation of study drug“1 (6.3)”“1 (8.3)”
Any infusion-related reaction“13 (81.3)”“7 (58.3)”
Fever“8 (50.0)”“1 (8.3)”
Chills“10 (62.5)”“0”
Any infection“6 (37.5)”“5 (41.7)”
Herpes simplex reactivation“2 (12.5)”“0”
Study limitations
Summary
  • Sample size and power: the authors describe a phase 2 study with a limited sample size and 80% power to detect differences in the primary outcome, which makes comparisons of secondary outcomes descriptive. The power calculation assumed 15 participants per group, 87% responders with Descartes-08, and 40% with placebo. Numerical differences in secondary scores did not meet the hierarchical threshold for formal testing, and placebo responses during early follow-up led to a lack of statistical significance in the secondary efficacy outcomes.
  • Analysis sets: of 45 participants who underwent leukapheresis, 9 (20.0%) were not randomized because fewer than six doses were manufactured. Of 36 randomized participants (safety population), the primary efficacy analysis included the 26 enrolled at an academic medical center with at least one postinfusion follow-up. The protocol specified sensitivity analyses in the overall ITT and per-protocol populations. The company's 2024 topline release reported the mITT population as 14 Descartes-08 and 12 placebo participants and the safety population as 19 and 17, where the published report gives 15 and 11, and 20 and 16.
  • Change of primary endpoint: on January 8, 2024, after 44 participants had enrolled and before unblinding and database lock, the primary outcome was changed from the MG-ADL score to the MGC score, and the 5-point MGC threshold, chosen to account for higher-than-expected baseline MGC scores, exceeds the 3-point change considered clinically meaningful. The primary efficacy population was defined in protocol amendment v4.2 (June 19, 2024).
  • Allocation and baseline imbalance: randomization had no stratification by site, and the authors state that this, the small sample, and the rate of participants not randomized likely led to unequal allocation. Disease duration and the rate of thymoma were higher in the placebo group, and triple seronegative participants (23.1%) were overrepresented compared with the general population, which the authors state affected the magnitude of the early placebo response. A transient effect of leukapheresis cannot be excluded.
  • Subgroups: subgroup analyses compared participants by AChR antibody status, early- or late-onset disease (a prespecified analysis), prior exposure to complement and FcRn inhibitors, and development of fever, and an analysis of cell dose and MGC response was post hoc. The authors state that the small sample and heterogeneous population severely limit inferences about subgroups, and that the difference between biologic-naive and biologic-exposed participants may represent a true difference in biology, an artifact of a small sample size, or more treatment-refractory disease.
  • Follow-up beyond month 3: all 11 placebo participants received open-label Descartes-08 after month 3, and month 4 to month 12 results are reported for the Descartes-08 group. As of a March 31, 2025 cutoff, the company reported that 12 of 15 Descartes-08 participants in the primary efficacy dataset completed month 12 and that 3 were lost to follow-up after month 3, 2 of whom were MGC responders at month 3.
  • Other author-stated limitations: radioimmunoassay antibody testing may be insufficiently sensitive to changes in antibody subtype, mode of activity, and epitope; the protocol held prednisone stable until month 6 and allowed no change in nonsteroidal immunosuppressants; and fevers, chills, and myalgias were more common with Descartes-08 and may have affected the assessment of severity scales.
  • Figures that differ between sources or within the report: sustained clinically meaningful response at month 12 is 83.0% in the abstract and 80.0% in the Discussion; minimum symptom expression is 33.0% in the abstract and 33.3% (4/12) in the Results; minimum symptom expression among biologic-naive participants is 55.60% in the abstract and 55.6% (5/9) in the Results, and the company's April 2025 release gives 57% (4/7) for biologic-naive participants with follow-up beyond month 3. The value −4.8 is reported both for the month-12 MG-ADL change and for the month-4 QMG change. The placebo MG-ADL change at month 3 in the AChR antibody-positive subgroup is 0.6 in the paper and −0.6 in a 2026 company slide presentation. The text reports prior or ongoing complement inhibitor use in the Descartes-08 group as “n = 7/15, 40.0%”.